Clinical trial
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung…
NCT00299390 · Bayer, Industry · Terminated
Key facts
| NCT number | NCT00299390 |
|---|---|
| Title | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer |
| Official title | Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as First Line Therapy in Chemotherapy Naive Patients With Extensive Disease (ED) Stage Small Cell Lung Cancer (SCLC) |
| Lead sponsor | Bayer, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | Sagopilone (BAY86-5302, ZK 219477) |
| Enrollment | 10 |
| Start date | Apr 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Mar 6, 2006 |
| Last update posted | Dec 31, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: